Cargando…
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987045/ https://www.ncbi.nlm.nih.gov/pubmed/24764534 http://dx.doi.org/10.1186/2051-1426-1-3 |
_version_ | 1782311821556842496 |
---|---|
author | Morales-Kastresana, Aizea Catalán, Elena Hervás-Stubbs, Sandra Palazón, Asis Azpilikueta, Arantza Bolaños, Elixabet Anel, Alberto Pardo, Julián Melero, Ignacio |
author_facet | Morales-Kastresana, Aizea Catalán, Elena Hervás-Stubbs, Sandra Palazón, Asis Azpilikueta, Arantza Bolaños, Elixabet Anel, Alberto Pardo, Julián Melero, Ignacio |
author_sort | Morales-Kastresana, Aizea |
collection | PubMed |
description | BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent but not NK-dependent. FINDINGS: In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are readily expressed by CD8(+) T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both killing mechanisms acting in a synergistic fashion. CONCLUSIONS: CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector cytolytic mechanisms that act in cooperation. |
format | Online Article Text |
id | pubmed-3987045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39870452014-04-17 Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb Morales-Kastresana, Aizea Catalán, Elena Hervás-Stubbs, Sandra Palazón, Asis Azpilikueta, Arantza Bolaños, Elixabet Anel, Alberto Pardo, Julián Melero, Ignacio J Immunother Cancer Short Report BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent but not NK-dependent. FINDINGS: In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are readily expressed by CD8(+) T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both killing mechanisms acting in a synergistic fashion. CONCLUSIONS: CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector cytolytic mechanisms that act in cooperation. BioMed Central 2013-05-29 /pmc/articles/PMC3987045/ /pubmed/24764534 http://dx.doi.org/10.1186/2051-1426-1-3 Text en Copyright © 2013 Morales-Kastresana et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Morales-Kastresana, Aizea Catalán, Elena Hervás-Stubbs, Sandra Palazón, Asis Azpilikueta, Arantza Bolaños, Elixabet Anel, Alberto Pardo, Julián Melero, Ignacio Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title_full | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title_fullStr | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title_full_unstemmed | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title_short | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb |
title_sort | essential complicity of perforin-granzyme and fas-l mechanisms to achieve tumor rejection following treatment with anti-cd137 mab |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987045/ https://www.ncbi.nlm.nih.gov/pubmed/24764534 http://dx.doi.org/10.1186/2051-1426-1-3 |
work_keys_str_mv | AT moraleskastresanaaizea essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT catalanelena essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT hervasstubbssandra essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT palazonasis essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT azpilikuetaarantza essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT bolanoselixabet essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT anelalberto essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT pardojulian essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab AT meleroignacio essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab |